Meme Kanserinin Farklı Moleküler Alt Tiplerinin Kök Hücre İşaretçisi, Sitokin Reseptörü ve Tümörle İlişkili Makrofaj İşaretçisi Dağılımı Açısından Değerlendirilmesi

Abstract

Breast cancer is a heterogeneous disease with different molecular subtypes, which determine the prognosis and response to the treatment. CD133 is a marker for cancer stem cells in tumor microenvironment with diagnostic/therapeutic importance. The tumor associated macrophages (TAM) interact with the cancer stem cells through the CXCR1 receptor. In this study, we hypothesized a possible difference in distribution of CD133, CXCR1 and CD163 antigens among different subtypes of breast cancer. Thus, we investigated the expression of these antigens in samples of the patients with luminal A (LA), luminal B (LB), HER2 overexpression (HER2OE), triple negative (TN) subtypes of breast cancer and control patients without cancer diagnosis. We applied indirect immunohistochemistry and evaluated immunostaining. CD133 expression was at periphery and CXCR1 expression was at the central areas of the tumor clusters. Cytoplasmic CXCR1, CD133 expressions and nuclear CD133 expression (prominent in TN subtype) were observed in patients. There was a statistically significant difference between groups for CD133 (p=0.004), CXCR1 (p=0.002) H-Score and M2 macrophages/whole TAM ratios (p=0.022). Between CD133 and CXCR1 expressions, there was a weak positive correlation (r=0.249, p=0.035). Due to compartment specific expression, agents targeting CXCR1 should reach to the central area of the tumor mass. Patients with TN subtype would benefit more from anti-CXCR1 treatment. Treatments, which target CXCR1 can also lower the expression of CD133 and vice versa. Keywords: Breast cancer, molecular subtypes, microenvironment, CD133, CXCR1, CD163, tumor associated macrophages, cancer stem cell